Treatment of severe multi-drug resistant Pseudomonas aeruginosa infections

Med Intensiva (Engl Ed). 2022 Sep;46(9):508-520. doi: 10.1016/j.medine.2022.06.014. Epub 2022 Jul 12.

Abstract

Pseudomonas aeruginosa is the microorganism most frequently involved in the main ICU-acquired infections, with special importance in ventilator associated pneumonia. Its importance lies, in addition to its high incidence in critically ill patients, in the severity of the infections it causes and in the difficulty of its antimicrobial treatment, directly related to the high percentage of resistance to antibiotics classically considered first-line. New active antibiotics have recently been developed against Pseudomonas aeruginosa, even against multi-drug resistant strains. This review analyzes both the differential characteristics of Pseudomonas aeruginosa infections and the new therapeutic options, focusing on multi-drug resistant Pseudomonas aeruginosa.

Keywords: Bacilo gramnegativo; Bacterias multirresistentes; Gramnegative bacillus; Multidrug-resistant bacteria; Neumonía asociada a la ventilación; Pseudomonas aeruginosa; Ventilator-associated pneumonia.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Drug Resistance, Multiple, Bacterial
  • Humans
  • Pneumonia, Ventilator-Associated* / drug therapy
  • Pseudomonas Infections* / drug therapy
  • Pseudomonas aeruginosa

Substances

  • Anti-Bacterial Agents